Novartis announces positive results from the primary analysis of ASC4FIRST, a pivotal Phase III trial in the treatment of newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

According to this analysis, its Scemblix (asciminib) showed major molecular response (MMR) rates superior to those of standard tyrosine kinase inhibitors (TKIs) at week 48, thus meeting its primary endpoints.

Novartis adds that Scemblix demonstrated a favorable safety and tolerability profile with fewer adverse events and treatment interruptions compared to standard TKIs, and that no new safety signals were observed.

Copyright (c) 2024 CercleFinance.com. All rights reserved.